UY34243A - Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares - Google Patents

Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares

Info

Publication number
UY34243A
UY34243A UY0001034243A UY34243A UY34243A UY 34243 A UY34243 A UY 34243A UY 0001034243 A UY0001034243 A UY 0001034243A UY 34243 A UY34243 A UY 34243A UY 34243 A UY34243 A UY 34243A
Authority
UY
Uruguay
Prior art keywords
assessing
markers
risk
methods
cardiovascular diseases
Prior art date
Application number
UY0001034243A
Other languages
English (en)
Inventor
Castillo Fernandez Sergio
Elosua Llanos Roberto
Marrugat De La Iglesia Jaume
Ordovas Munoz Jose Maria
Salas Perez-Rasilla Eduardo
Salgado Gomez Joan
Original Assignee
Gendiag Exe Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gendiag Exe Sl filed Critical Gendiag Exe Sl
Publication of UY34243A publication Critical patent/UY34243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a un método para reclasificar un sujeto para evaluación del riesgo más apropiada que la obtenida usando los algoritmos para esa estimación de riesgos tal como, pero no limitada a, Framingham, Regicor, Score, Procamor Qrisk, basada en la presencia de diferentes polimorfismos. La invención también se refiere a un método para determinar el riesgo de padecer una enfermedad car diovascular combinando la ausencia o la presencia de uno o más marcadores polimórficos en una muestra del sujeto con factores de riesgo convencionales para CVD así como también medios implementados por computadora para llevar a cabo dicho método.
UY0001034243A 2011-08-05 2012-08-03 Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares UY34243A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11176695.2A EP2554679B1 (en) 2011-08-05 2011-08-05 Genetic markers for cardiovascular disease risk assessment

Publications (1)

Publication Number Publication Date
UY34243A true UY34243A (es) 2013-02-28

Family

ID=46604315

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034243A UY34243A (es) 2011-08-05 2012-08-03 Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares

Country Status (14)

Country Link
US (1) US11814673B2 (es)
EP (2) EP2554679B1 (es)
AR (1) AR087445A1 (es)
BR (1) BR112014002856A2 (es)
CA (1) CA2844103C (es)
DK (1) DK2554679T3 (es)
ES (2) ES2573648T3 (es)
HU (1) HUE029534T2 (es)
MX (1) MX356640B (es)
PL (1) PL2554679T3 (es)
PT (1) PT2739750T (es)
SA (1) SA112330754B1 (es)
UY (1) UY34243A (es)
WO (1) WO2013020870A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077823B2 (en) 2011-08-05 2024-09-03 Genincode Plc Risk assessment for cardiovascular disease
EP2843056B8 (en) * 2013-08-30 2019-06-26 GENINCODE UK, Ltd. Risk markers for cardiovascular disease in patients with chronic kidney disease
WO2015127517A1 (en) * 2014-02-27 2015-09-03 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
US20190295727A1 (en) * 2018-03-23 2019-09-26 American Heart Association, Inc. System and Method for Assessing Heart Health and Communicating the Assessment to a Patient
CN110840891A (zh) * 2018-08-20 2020-02-28 山西医科大学 降压药潘必定（Pempidine）可作为新型抗心律失常药物
CN111354464B (zh) * 2018-12-24 2024-05-17 深圳先进技术研究院 Cad预测模型建立方法、装置以及电子设备
CN109859847A (zh) * 2019-02-15 2019-06-07 京东方科技集团股份有限公司 电子设备、体重管理收益预测装置及存储介质
WO2021185936A1 (en) 2020-03-17 2021-09-23 Chen Zhao System and method for generating personalized treatments
CN116348615A (zh) * 2020-10-20 2023-06-27 遗传技术有限公司 评估患病风险的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6159693A (en) 1998-03-13 2000-12-12 Promega Corporation Nucleic acid detection
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
CA2558458A1 (en) * 2004-03-05 2005-09-22 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
KR101571523B1 (ko) 2007-02-21 2015-11-24 디코드 제네틱스 이에이치에프 심혈관 질환과 연관된 유전적 감수성 변이
US20110014613A1 (en) * 2009-04-01 2011-01-20 Pfuetzner-Riehn Elisabeth Genotyping for Risk of Atherosclerosis
EP2264183B1 (en) * 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
US20110269735A1 (en) * 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

Also Published As

Publication number Publication date
EP2739750A1 (en) 2014-06-11
ES2657746T3 (es) 2018-03-06
MX356640B (es) 2018-06-07
WO2013020870A4 (en) 2013-04-25
PT2739750T (pt) 2018-02-13
CA2844103A1 (en) 2013-02-14
EP2739750B1 (en) 2017-11-15
BR112014002856A2 (pt) 2017-02-21
DK2554679T3 (en) 2016-04-04
US11814673B2 (en) 2023-11-14
EP2554679A1 (en) 2013-02-06
US20140342355A1 (en) 2014-11-20
SA112330754B1 (ar) 2015-11-08
CA2844103C (en) 2019-03-12
PL2554679T3 (pl) 2016-09-30
WO2013020870A1 (en) 2013-02-14
HUE029534T2 (hu) 2017-02-28
EP2554679B1 (en) 2016-03-02
MX2014001463A (es) 2014-05-14
AR087445A1 (es) 2014-03-26
ES2573648T3 (es) 2016-06-09

Similar Documents

Publication Publication Date Title
UY34243A (es) Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares
SMT201700003B (it) Didropiridoni come inibitori del fattore xia
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
CO7020912A2 (es) Inhibidores de bromodominios
CO7091177A2 (es) Inhibidores de la beta-secretasa
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
BR112013025006A2 (pt) composições e métodos para inibição de expressão do gene tmprss6
BR112015001211A2 (pt) novos ácidos 5-aminotetra-hidroquinolina-2-carboxílicos e sua utilização
UY34550A (es) Bencilpirazoles sustituidos
UY34134A (es) Contenedor aislado
UY34538A (es) Heteroarilos y usos de los mismos
BR112013027716A2 (pt) gavetas rápidas com rolos e rampa
UY4175Q (es) Reloj pulsera
BR112013028512A2 (pt) cápsula
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
BR112013024211A2 (pt) tratamento de tumores sólidos
BR112013019280A2 (pt) composições wnt e métodos para sua utilização
FI20126266A (fi) Pehmopaperin mittaus
CO6940375A2 (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
BR112015023440A2 (pt) torradeira para tortilha aperfeiçoada
BR112013028251A2 (pt) polipeptídeo